The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NVS | +19.7% | +100.04% | +14.87% | +3,852% |
| S&P | +16.23% | +94.45% | +14.22% | +1,649% |
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Eli Lilly, Johnson & Johnson, and AbbVie command the healthcare sector.
Both have crushed the market in 2025.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $14.28B | 14.3% |
| Gross Profit | $10.91B | 17.0% |
| Gross Margin | 76.38% | 1.7% |
| Market Cap | $229.63B | 10.2% |
| Market Cap / Employee | $3.03M | 0.0% |
| Employees | 75.9K | -0.2% |
| Net Income | $4.09B | 26.2% |
| EBITDA | $5.93B | 16.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.66B | -15.8% |
| Accounts Receivable | $9.06B | 10.1% |
| Inventory | 6.3K | 9.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $24.06B | 13.4% |
| Short Term Debt | $8.57B | 10.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 13.61% | 3.9% |
| Return On Invested Capital | 14.75% | 1.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $6.43B | 39.4% |
| Operating Free Cash Flow | $6.77B | 38.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 13.21 | 16.46 | 17.31 | 17.41 | 30.16% |
| Price to Book | 5.58 | 4.49 | 5.00 | 6.18 | 12.86% |
| Price to Sales | 4.77 | 3.88 | 4.26 | 4.43 | -3.11% |
| Price to Tangible Book Value | -20.65 | -20.45 | -28.88 | -16.85 | -25.07% |
| Price to Free Cash Flow TTM | 32.68 | 22.60 | 22.38 | 20.58 | -39.23% |
| Enterprise Value to EBITDA | 41.23 | 39.64 | 42.66 | 44.32 | -5.58% |
| Free Cash Flow Yield | 3.1% | 4.4% | 4.5% | 4.9% | 64.56% |
| Return on Equity | 29.0% | 26.3% | 33.0% | 32.8% | 51.94% |
| Total Debt | $32.16B | $31.26B | $31.27B | $32.64B | 12.59% |
We examine three biotech companies' past performances and future outlooks.
Here’s how CAR-T therapies did in their first full year on the market.
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
The 21st Century Cures Act ignites innovation with perks to biopharma and medical device makers. Also, Kite Pharma and Novartis prep plans to pitch their CAR-T cancer therapies to the FDA.
NVS earnings call for the period ending December 31, 2024.
NVS earnings call for the period ending September 30, 2024.
NVS earnings call for the period ending June 30, 2024.
NVS earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
